Lamivudine Reduces Healthcare Resource Use when Added to Zidovudine-Containing Regimens in Patients with HIV Infection
- 1 January 1999
- journal article
- clinical trial
- Published by Springer Nature in PharmacoEconomics
- Vol. 15 (1), 13-22
- https://doi.org/10.2165/00019053-199915001-00002
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- A prospective cost-consequence analysis of adding lamivudine to zidovudine-containing antiretroviral treatment regimens for HIV infection in the US.PharmacoEconomics, 1999
- A Prospective Evaluation of the Cost Effectiveness of Adding Lamivudine to Zidovudine-Containing Antiretroviral Treatment Regimens in HIV InfectionPharmacoEconomics, 1999
- The cost-effectiveness of treatment with lamivudine and zidovudine compared with zidovudine alone: a comparison of Markov model and trial data estimates.1998
- Antiretroviral Therapy for HIV Infection in 1998JAMA, 1998
- Modelling the Potential Economic Impact of Viral Load???Driven Triple Drug Combination Antiretroviral TherapyPharmacoEconomics, 1998
- Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centresAIDS, 1997
- Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection.PharmacoEconomics, 1997
- Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial.1997
- The Economic Costs of Caring for People with HIV Infection and AIDS in England and WalesPharmacoEconomics, 1996
- Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic MillimeterNew England Journal of Medicine, 1995